Analysis of Mtor Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.

Yan Kong,Lu Si,Yi Q. Li,Xiao W. Wu,Jie Dai,Huan Tang,Meng Ma,Zhi H. Chi,Xi N. Sheng,Chuan L. Cui,Jun Guo

DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.9049

IF: 45.3

2015-01-01

Journal of Clinical Oncology

Abstract:9049 Background: mTOR is a validated target in cancer treatment. mTOR mutations are estimated to be 2.46% of all cancers and 5.76% of cutaneous melanoma. However, mTOR mutations in other types of melanoma have not been reported. Methods: This study involved tumor samples from 412 Chinese melanoma patients, including 210 acral melanomas, 105 mucosal melanomas, 30 melanomas on skin with chronic sun-induced damage and 58 melanomas on skin without chronic sun-induced damage. Tissue samples were analyzed for mutations in all exons of mTOR gene in genomic DNA by Sanger sequencing. Mutation status was confirmed using Agilent’s sureselect target enrichment system. HEK293T cells stably expressing mutant mTOR were constructed by TALEN (Transcription Activator-like Effector Nucleases). Function of mTOR mutants in these cells and in vitro sensitivity of mTOR gain-of-function mutations to PI3K-AKT-mTOR pathway inhibitors were analyzed. Results: The overall incidence of somatic mutations within the mTOR gene was 10.4% (43/412). Increased mTOR mutations were relatively more frequent in acral (11.0%) and mucosal (14.4%) melanomas than in CSD (6.7%) and Non-CSD (3.4%) melanomas. Of the 43 cases with mTOR mutations, 41 different mutations were detected, affecting 25 different exons. Point mutations resulting in single amino acid substitutions (totaling 40 mutations detected in 43 patients) were the most common type of mTOR mutation. The median survival time for melanoma patients with mTOR mutation was significantly shorter than that for patients without mTOR mutation (P = 0.028). Transient expression of several mTOR mutants in HEK293 cells strongly activated the mTOR/p70S6K pathway. In HEK293 cells with stable expression of H1968Yor P2213S mTOR mutants, LY294002 and AZD5363 showed higher potency than Temsirolimus or BYL719 in inhibiting the mTOR/p70S6K pathway. Conclusions: These data demonstrate that mTOR mutations are more frequent in Chinese melanoma patients than in Caucasian melanoma patients. mTOR mutations is a worse prognostic factor in Chinese melanoma patients. Clinical trials with PI3K-AKT-mTOR pathway inhibitors may be beneficial for melanoma patients with mTOR mutations.